Related Experiment Videos
Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome
T Inaba1, C Shimazaki, T Sumikuma
1Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan. inaba178@koto.kpu-m.ac.jp
Insights
Thy-1 (CD90) is expressed on CD34+ bone marrow cells in myelodysplastic syndrome (MDS) patients, persisting during disease progression. High Thy-1 expression may indicate a poorer prognosis in MDS.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Thy-1 (CD90) is a cell surface glycoprotein expressed on various cell types, including hematopoietic stem cells.
- The role of Thy-1 expression in MDS pathogenesis and progression is not fully understood.
Purpose of the Study:
- To analyze the expression of Thy-1 (CD90) on CD34+ bone marrow mononuclear cells (BMMNC) in patients with myelodysplastic syndrome (MDS).
- To investigate the correlation between Thy-1 expression and clinical/cytogenetic features of MDS.
- To assess the dynamics of Thy-1 expression during disease progression, including leukemic transformation.
Main Methods:
- Two-color flow cytometry was used to analyze Thy-1 expression on CD34+ BMMNC from 25 MDS patients.
- Patients were categorized based on MDS subtypes (RAEB, RAEB-t).
- Correlation with chromosomal abnormalities and serial analysis before and after leukemic transformation were performed.
Main Results:
- Thy-1 expression on CD34+ BMMNC was detected in a subset of MDS patients, particularly those with refractory anemia with excess of blasts (RAEB).
- Higher Thy-1 expression (>20%) was observed in 55.6% of RAEB patients and 12.5% of RAEB in transformation (RAEB-t) patients.
- Thy-1 expression remained stable before and after leukemic transformation, suggesting it is maintained during disease progression.
- Specific chromosomal abnormalities (-5/5q-, -18) may be associated with Thy-1 expression in MDS.
Conclusions:
- Thy-1 is expressed on CD34+ BMMNC in certain MDS patients and is maintained throughout disease progression.
- Thy-1 expression does not appear essential for leukemic transformation in MDS.
- Elevated Thy-1 expression in MDS patients might be linked to a poorer prognosis compared to those with lower expression.
Abstract:
We analyzed the expression of Thy-1 (CD90) antigen on CD34+ bone marrow mononuclear cells (BMMNC) obtained from 25 patients with myelodysplastic syndrome (MDS) by two-color flow cytometry. Five of nine patients (55.6%) with refractory anemia with excess of blasts (RAEB) and two of 16 (12.5%) with RAEB in transformation (RAEB-t) showed more than 20% of Thy-1 expression of their CD34+ BMMNC. Regarding chromosomal abnormalities, -5/5q- or -18 might be correlated with the expression of Thy-1 on CD34+ BMMNC in MDS. Nine patients were analyzed twice, once before and once after leukemic transformation and showed no significant change in Thy-1 expression. These results show that Thy-1 was expressed on CD34+ BMMNC in certain patients with MDS before leukemic transformation and that it was maintained during the disease progression. In contrast, expression of Thy-1 did not seem essential to the leukemic transformation in MDS though the patients with high Thy-1 expression might have poorer prognosis compared with those with low Thy-1 expression.